RNA therapies have emerged as a promising treatment modality, with the potential to target and alter genes, modulate protein functions and broaden the range of druggable targets, thereby paving way for new avenues in disease diagnosis and treatment. With rise in government initiatives for early commercialization of pipeline therapies and active involvement of RNA therapeutics investors, we anticipate a variety of novel RNA based therapeutics to be developed, presenting lucrative opportunities for both short- and long-term investors. The financial opportunity within the RNA therapeutics market has been analyzed across the following segments:  Type of Therapy  mRNA Vaccines and Therapeutics  RNAi Therapeutics  RNA Aptamers  Therapeutic Area  Infectious Diseases  Genetic Disorders  Haematological Disorders  Metabolic Disorders  Ocular Disorders  Oncological Disorders  Renal Disorders  Route of Administration  Intradermal  Intramuscular  Intravenous  Intravitreal  Ophthalmic  Subcutaneous  Key Geographies  North America  Europe  Asia-Pacific  Middle East and North Africa  Latin America The Investor Series: Opportunities in the RNA Therapeutics Market (mRNA Therapeutics and Vaccines, RNAi Therapeutics, and RNA Aptamers), detailed profiles of key public ventures engaged in the development of RNA therapeutics; each profile features a brief overview of the company, along with information on its management team, insights from its balance sheet (if available), as well as details related to its product portfolio, recent developments and key financials (including company investment highlights, company fundamental and company technical analysis).  Arcturus Therapeutics  Ascletis Pharma  Avidity Biosciences  BioNtech  CanSino Biologics  Gritstone bio  IVERIC bio  Moderna  Phio Pharmaceuticals  Vir Biotechnology Table of Contents Excel Deliverables 1. Innovators and Products Dataset 2. RNA therapeutics Funding and Investment Analysis 3. Company Valuation Analysis 4. Fundamental Financial Analysis 5. Technical Financial Analysis 6. Business Risk Analysis 7. Market Forecast and Opportunity Analysis 8. Return on Investment PowerPoint Deliverable 1. Context 2. Project Approach 3. Project Objective 4. Executive Summary Section I: Introduction to RNA Therapeutics and Innovators Landscape 5. The RNA Therapeutics Market 6. RNA Therapeutics: Innovators Landscape 7. RNA Therapeutics: Products Landscape and Company Health Indexing 8. Value Proposition Analysis 9. Company Competitiveness Analysis Section II: Analysis of RNA therapeutics Investment and Company Valuation 10. Funding and Investment Analysis 11. Company Valuation Analysis Section III: Financial Analysis and Assessment of Business Risks 12. Financial Analysis of Public Ventures 13. Company Profiles of Public Ventures 14. Business Risk Assessment Section IV: Market Forecast and Opportunity Analysis 15. Market Forecast and Opportunity Analysis Section V: Analysis of Returns on Investment and Key Acquisition Targets 16. Analysis of Return on Investment 17. Key Acquisition Targets 18. Conclusion 19. Appendices To view more details on this report, click on the link https://www.rootsanalysis.com/reports/opportunities-in-rna-therapeutics-market.html Learn from experts: do you know about these emerging industry trends? T-cell Immunotherapies: The Future of Modern Cancer Treatments Monkeypox: Disease Overview, Transmission and Diagnosis Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 [email protected]